Avance Clinical to Showcase Oncology Leadership at ASCO Annual Meeting 2026

Avance Clinical’s integrated oncology capability is delivered through its Oncology Center of Excellence, which brings together scientific, medical, regulatory, andoperational leadership to support sponsors confidently across the full earlydevelopment journey and beyond.

A key differentiator for Avance Clinical is the ability to launch early-phase oncology studies in Australia, where favourable regulatory pathways, rapid start-up timelines, and access to high-quality clinical data provide a strong foundation for global development. Attendees are encouraged to speak with Gabriel Kremmidiotis, Chief Scientific Officer, about initiating oncology programs in Australia and leveraging the Australian Advantage, which provides up to 43.5% Australian Government tax rebate to accelerate early clinical development.

George Peoples, MD, FACS, Executive Medical Director, Oncology provides therapeutic area leadership within the Oncology Center of Excellence at Avance Clinical. Dr Peoples works closely with sponsors to advise on indication-specific considerations, protocol design strategy, and early development decision-making across complex oncology programs.

Regulatory strategy across the entire oncology development lifecycle is led by Dalal Murgai, Global Head of Regulatory Affairs at Avance Clinical. With more than 20 years of experience guiding global regulatory programs, Dalal provides end-to-end regulatory support – from early scientific advice and first-in-human planning through to late-phase development and global submissions. Sponsors are encouraged to speak with Dalal about building aligned, region-appropriate regulatory strategies that support seamless progression as oncology programs expand internationally.

With more than 260 oncology trials conducted, Avance Clinical brings significant operational depth across a broad range of tumour types, including haematological malignancies, solid tumours, and rare oncology indications.

Avance Clinical’s ClinicReady and GlobalReady delivery model enables biotech companies to initiate early-phase oncology studies efficiently in Australia and Asia, leveraging streamlined regulatory pathways and established site networks, before seamlessly expanding into the United States and other global regions as programs mature. This approach supports faster study start-up, high-quality data generation, and global read-out readiness for pivotal decision-making.

At ASCO 2026, attendees will have the opportunity to meet Gabriel, George and Dalal as well as other senior members of Avance Clinical’s for in-depth discussions on trial feasibility, region-by-region development strategies, and approaches to accelerating timelines while maintaining rigorous scientific and operational standards.